Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s11373-008-9247-x.

Title:
Immunotherapy for head and neck cancer | Journal of Biomedical Science
Description:
Head and neck cancer represents a challenging disease. Despite recent treatment advances, which have improved functional outcomes, the long-term survival of head and neck cancer patients has remained unchanged for the past 25 years. One of the goals of adjuvant cancer therapy is to eradicate local regional microscopic and micrometastatic disease with minimal toxicity to surrounding normal cells. In this respect, antigen-specific immunotherapy is an attractive therapeutic approach. With the advances in molecular genetics and fundamental immunology, antigen-specific immunotherapy is being actively explored using DNA, bacterial vector, viral vector, peptide, protein, dendritic cell, and tumor-cell based vaccines. Early phase clinical trials have demonstrated the safety and feasibility of these novel therapies and the emphasis is now shifting towards the development of strategies, which can increase the potency of these vaccines. As the field of immunotherapy matures and as our understanding of the complex interaction between tumor and host develops, we get closer to realizing the potential of immunotherapy as an adjunctive method to control head and neck cancer and improve long-term survival in this patient population.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {๐Ÿ“š}

  • Education
  • Health & Fitness
  • Science

Content Management System {๐Ÿ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of link.springer.com audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {๐Ÿ’ธ}

We don't see any clear sign of profit-making.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {๐Ÿ”}

google, scholar, pubmed, cas, cancer, neck, head, human, cell, res, oncol, dna, gene, vaccines, papillomavirus, vaccine, clin, factor, immunotherapy, growth, patients, carcinoma, hung, squamous, receptor, cells, tumor, immunol, van, antigen, hpv, tumors, ther, article, phase, clinical, encoding, antitumor, therapeutic, expression, kim, pai, treatment, advanced, rev, chen, virus, cervical, study, cetuximab,

Topics {โœ’๏ธ}

granulocyte-macrophage colony-stimulating factor monoclonal antibody h-r3 specific anti-tumor immunotherapy ctl-mediated killing idiotype-cytokine fusion proteins anti-tumor effects generated tumor-cell based vaccines allogenic antibody-mediated identification month download article/chapter epigallocatechin-3-gallate enhances cd8+ t-cell immunity potent tumour regression activating rho-family gtpases neck squamous-cell carcinomas human papillomavirus vaccines anti-tumour activity adenovirus e1-induced tumors van den eynde plasmid-encoded flt-3 ligand dna vaccine encoding intracellular targeting strategies autologous tumor-infiltrating lymphocytes small-cell lung cancer anti-tumor activity anti-tumor effects e7 protein delivered cell line recognizing improve long-term survival prime-boost vaccination strategy oncogenic human papillomavirus e1a-specific cytotoxic tyrosine kinase 3-ligand advanced epithelial-derived cancer antigen-specific immunotherapy lymphocyte molecules cd28 wild-type p53 antigen-specific agents anti-tumor immunity plasmid dna vaccines enhances vaccine potency human papilloma vaccines papilloma high-grade lesions human papillomavirus infection de la garza squamous cell carcinomas van der bruggen prime/boost immunotherapy achieving selective killing dna vaccine administered b7-transfected melanoma cells

Questions {โ“}

  • Balz V, Scheckenbach K, Gotte K, Bockmuhl U, Petersen I, Bier H (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated?
  • Roden R, Wu TC (2006) How will HPV vaccines affect cervical cancer?

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:Immunotherapy for head and neck cancer
         description:Head and neck cancer represents a challenging disease. Despite recent treatment advances, which have improved functional outcomes, the long-term survival of head and neck cancer patients has remained unchanged for the past 25ย years. One of the goals of adjuvant cancer therapy is to eradicate local regional microscopic and micrometastatic disease with minimal toxicity to surrounding normal cells. In this respect, antigen-specific immunotherapy is an attractive therapeutic approach. With the advances in molecular genetics and fundamental immunology, antigen-specific immunotherapy is being actively explored using DNA, bacterial vector, viral vector, peptide, protein, dendritic cell, and tumor-cell based vaccines. Early phase clinical trials have demonstrated the safety and feasibility of these novel therapies and the emphasis is now shifting towards the development of strategies, which can increase the potency of these vaccines. As the field of immunotherapy matures and as our understanding of the complex interaction between tumor and host develops, we get closer to realizing the potential of immunotherapy as an adjunctive method to control head and neck cancer and improve long-term survival in this patient population.
         datePublished:2008-04-05T00:00:00Z
         dateModified:2008-04-05T00:00:00Z
         pageStart:275
         pageEnd:289
         sameAs:https://doi.org/10.1007/s11373-008-9247-x
         keywords:
            Head and neck cancer
            Head and neck squamous cell carcinoma
            Tumor-specific antigens
            Human papillomavirus
            Antigen-specific immunotherapy
            Tumor immunology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11373-008-9247-x/MediaObjects/11373_2008_9247_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11373-008-9247-x/MediaObjects/11373_2008_9247_Fig2_HTML.gif
         isPartOf:
            name:Journal of Biomedical Science
            issn:
               1423-0127
               1021-7770
            volumeNumber:15
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Annie A. Wu
               affiliation:
                     name:The Johns Hopkins Medical Institutions
                     address:
                        name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kevin J. Niparko
               affiliation:
                     name:The Johns Hopkins Medical Institutions
                     address:
                        name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sara I. Pai
               affiliation:
                     name:The Johns Hopkins Medical Institutions
                     address:
                        name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immunotherapy for head and neck cancer
      description:Head and neck cancer represents a challenging disease. Despite recent treatment advances, which have improved functional outcomes, the long-term survival of head and neck cancer patients has remained unchanged for the past 25ย years. One of the goals of adjuvant cancer therapy is to eradicate local regional microscopic and micrometastatic disease with minimal toxicity to surrounding normal cells. In this respect, antigen-specific immunotherapy is an attractive therapeutic approach. With the advances in molecular genetics and fundamental immunology, antigen-specific immunotherapy is being actively explored using DNA, bacterial vector, viral vector, peptide, protein, dendritic cell, and tumor-cell based vaccines. Early phase clinical trials have demonstrated the safety and feasibility of these novel therapies and the emphasis is now shifting towards the development of strategies, which can increase the potency of these vaccines. As the field of immunotherapy matures and as our understanding of the complex interaction between tumor and host develops, we get closer to realizing the potential of immunotherapy as an adjunctive method to control head and neck cancer and improve long-term survival in this patient population.
      datePublished:2008-04-05T00:00:00Z
      dateModified:2008-04-05T00:00:00Z
      pageStart:275
      pageEnd:289
      sameAs:https://doi.org/10.1007/s11373-008-9247-x
      keywords:
         Head and neck cancer
         Head and neck squamous cell carcinoma
         Tumor-specific antigens
         Human papillomavirus
         Antigen-specific immunotherapy
         Tumor immunology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11373-008-9247-x/MediaObjects/11373_2008_9247_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11373-008-9247-x/MediaObjects/11373_2008_9247_Fig2_HTML.gif
      isPartOf:
         name:Journal of Biomedical Science
         issn:
            1423-0127
            1021-7770
         volumeNumber:15
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Annie A. Wu
            affiliation:
                  name:The Johns Hopkins Medical Institutions
                  address:
                     name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kevin J. Niparko
            affiliation:
                  name:The Johns Hopkins Medical Institutions
                  address:
                     name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sara I. Pai
            affiliation:
                  name:The Johns Hopkins Medical Institutions
                  address:
                     name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Biomedical Science
      issn:
         1423-0127
         1021-7770
      volumeNumber:15
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Johns Hopkins Medical Institutions
      address:
         name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
         type:PostalAddress
      name:The Johns Hopkins Medical Institutions
      address:
         name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
         type:PostalAddress
      name:The Johns Hopkins Medical Institutions
      address:
         name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Annie A. Wu
      affiliation:
            name:The Johns Hopkins Medical Institutions
            address:
               name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:Kevin J. Niparko
      affiliation:
            name:The Johns Hopkins Medical Institutions
            address:
               name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
               type:PostalAddress
            type:Organization
      name:Sara I. Pai
      affiliation:
            name:The Johns Hopkins Medical Institutions
            address:
               name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
      name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
      name:Department of Otolaryngology/Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {๐Ÿ”—}(267)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Particles.js
  • Prism.js

CDN Services {๐Ÿ“ฆ}

  • Crossref

4.44s.